EMEA-002635-PIP02-21
Key facts
| Active substance |
Repotrectinib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0542/2021
|
| PIP number |
EMEA-002635-PIP02-21
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic neoplasms)
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Bristol-Myers Squibb Pharma EEIG
E-mail: medical.information@bms.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|